Evaluation of serum antibodies against SARS-CoV-2 in healthcare workers who participated in the operation of charter flights for the evacuation of Japanese residents from Hubei Province

Tetsuya Suzuki, M.D.^{1,2}, Kayoko Hayakawa, M.D., Ph.D.¹, Akira Ainai, Ph.D.³, Naoko Iwata-Yoshikawa, D.V.M., Ph.D.³, Kaori Sano, D.V.M., Ph.D.³, Noriyo Nagata, D.V.M., Ph.D.³, Tadaki Suzuki, M.D., Ph.D.³, Yuji Wakimoto, M.D.¹, Yutaro Akiyama, M.D.¹, Yusuke Miyazato, M.D.¹, Keiji Nakamura, M.D.¹, Satoshi Ide, M.D.^{1,2}, Hidetoshi Nomoto, M.D.^{1,2}, Takato Nakamoto, M.D.¹, Masayuki Ota, M.D.¹, Yuki Moriyama, M.D.^{1,2}, Yuko Sugiki, R.N.^{4, 5}, Sho Saito, M.D.^{1,2}, Shinichiro Morioka, M.D.^{1,2}, Masahiro Ishikane, M.D., Ph.D.¹, Noriko Kinoshita, M.D.^{1,2}, Satoshi Kutsuna, M.D., Ph.D.¹, Norio Ohmagari, M.D., M.Sc., Ph.D.^{1, 2}

1) Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

2) Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.

3) Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan

4) Infection Control Team, National Center for Global Health and Medicine, Tokyo, Japan

5) Department of Nursing, National Center for Global Health and Medicine, Tokyo, Japan

20 **Key words:** COVID-19; personal protective equipment; serum antibody; infection control

21 **Running head:** SARS-CoV-2 antibodies in healthcare workers

22 **Corresponding Author:**

23 Tetsuya Suzuki

24 Disease Control and Prevention Center

25 National Center for Global Health and Medicine, Tokyo, Japan

26 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

27 Tel: +81-3-3202-7181

28 Fax: +81-3-3207-1038

29 E-mail: tesuzuki@hosp.ncgm.go.jp

30

31 **Summary**

32 There are several recommendations for the use of personal protective equipment (PPE) against
 33 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the selection of
 34 appropriate PPE for the current situation remains controversial. We measured serum antibody titers
 35 for SARS-CoV-2 in 10 participants who were engaged in the operation of charter flights for the
 36 evacuation of Japanese residents from Hubei Province. All participants wore PPE in accordance with
 37 Centers for Disease Control and Prevention guidelines. A total of 17 samples were tested, and all
 38 were seronegative. Hence, we conclude that the current PPE recommendation is effective to protect
 39 healthcare workers from SARS-CoV-2 infection.

40

Text

Although there are several recommendations for personal protective equipment (PPE) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (1, 2), the selection of appropriate PPE according to the current situation remains a matter of debate. There are reports on the incidence of coronavirus disease (COVID-19) among healthcare workers (3), which puts them under tremendous stress. The National Center for Global Health and Medicine (NCGM) helped the operation of charter flights for the evacuation of Japanese residents from Hubei Province from the end of January to mid-February 2020 (4). In the present study, we evaluated the efficacy of PPE against SARS-CoV-2 infection among hospital staff who were engaged in the operation of charter flights by measuring their serum antibody levels. In addition, we used a questionnaire for self-evaluation of the PPE wearing status.

Hospital staff who participated in the operation were recruited for this study. All staff wore PPE, which includes N95 mask, gown, gloves, disposable cap, and eye protection, in accordance with the Centers for Disease Control and Prevention (CDC) guidelines. The details of this operation are provided in a previous report (4). The doctor who collected the pharyngeal swab had used a coverall to minimize the risk of body surface contamination due to infected secretions and droplets. Enhanced hand hygiene using an alcohol-based hand sanitizer was practiced.

Blood samples were collected at enrollment (after February 14th) and at every 2 weeks after enrollment until 4 weeks after the final participation in the evacuation operation. At enrollment, participants were asked to answer the web-form self-reporting questionnaire about their PPE and their compliance. This study was reviewed and approved by the Ethics Committee of the Center Hospital of National Center for Global Health and Medicine. Written informed consent was obtained from all participants.

Serum antibody titers were measured using a two-step assay. First, samples were screened using enzyme-linked immunosorbent assay (ELISA). Positive samples were then re-examined, by

neutralization assay, for the presence or absence of specific antibodies against SARS-CoV-2. The details of this method have been reported previously (5). The participants of the previous study and this present study are not overlapped.

Japanese government-chartered aircrafts were operated on 3 times in January and twice in February, 2020. The number of people who were screened at our hospital on the respective dates was 199, 197, 140, 194, and 63, respectively. The number of positive cases was 3 (1), 2 (3), 2 (1), 1, and 0, respectively (numbers in parentheses indicate the number of people whose results were initially negative from the samples obtained at NCGM but later became positive) (6-9). Thus, the final chance for participants to come in contact with COVID-19 patients was in early February, but two participants had other chances of occupational exposure to COVID-19 in February.

Ten healthcare workers (2 nurses, 5 doctors, and 3 clerical staff) were enrolled. Five of them were male. Eight participants responded to a web-form questionnaire. Their characteristics are listed in Table 1. Among those who answered the questionnaire, 4 were in their 40s, 3 were in their 30s, and 1 was in his/her 50s. Their median compliance with PPE was 90% (range 70-100%, n=8). A total of 17 blood samples were collected from 10 participants. Of them, 8 had their first samples collected around late February, 2020. Before blood sampling, 25% of them (n=2/8) noticed some respiratory symptoms. Six participants underwent more than 2 blood samplings at intervals of approximately 2 weeks. Five samples from 2 participants tested positive on ELISA screening, but none of them remained positive after the neutralization assay. Thus, all samples from all participants were seronegative.

We conclude that healthcare workers who participated in the operation of charter flights for the evacuation of Japanese residents from Hubei Province, China, were seronegative for SARS-CoV-2. Thus, PPE in accordance with the CDC guidelines is effective in protecting healthcare staff from COVID-19. Along with previous studies (10, 11), these results suggest that appropriate PPE prevents healthcare workers from contracting COVID-19. The unique aspects of our study are

as follows: (a) participants included clerical staff who are usually not familiar with the use of PPE and (b) a short period of training would enable them to use PPE appropriately. In addition, to maximize the sensitivity and specificity, we used a careful, two-step evaluation for the serostatus.

In our study, the first blood sample was obtained between late February and early March, 2020. Because there were no laboratory-confirmed COVID-19 patients in the 5th flight, their final potential exposure was on early February, 2020. The duration was sufficient to attain a seropositive status, if the infection was established among the participants (12).

There are some limitations to this study. First, recall bias is inevitable because the questionnaire used was self-reporting. Second, compared to inpatient care, opportunities for exposure to COVID-19 cases were less intense in this cohort. Third, the setting of this study is different from the routine medical exposure, and thus, the results of our study might not be adaptable to clinical practice.

In conclusion, this study demonstrates the effectiveness of PPE in protecting a wide range of healthcare workers from being infected with SARS-CoV-2. Sufficient PPE supply for healthcare staff is essential to avoid the spread of nosocomial infections. Further studies including a large number of participants are required to support and validate the effectiveness of PPE.

Funding: This work was supported in part by the Emerging/Re-emerging Infectious Diseases Project of Japan, from the Japan Agency for Medical Research and Development, AMED under grant numbers JP19fk0108104 and JP19fk0108110, and Japan's National Center for Global Health and Medicine (grant number 20A2003D).

Ethical Approval: This study was reviewed and approved by the Ethics Committee of the Center Hospital of the National Center for Global Health and Medicine. Written informed consent was

obtained from all participants.

Acknowledgement: The authors acknowledge BZ, KT, FN, NM, JL, YG, YO, JK, ST, and BS for their help in sample collection.

Conflict of Interest: None to declare.

References

1. World Health Organization. Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance, 19 March 2020. Available at <https://apps.who.int/iris/handle/10665/331498> Accessed August 15, 2020.
2. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. Available at <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html> Accessed August 15, 2020.
3. Anelli F, Leoni G, Monaco R, et al. Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak. *BMJ*. 2020;368:m1254.
4. Hayakawa K, Kutsuna S, Kawamata T, et al. SARS-CoV-2 infection among returnees on charter flights to Japan from Hubei, China: a report from National Center for Global Health and Medicine. *Glob Health Med*. 2020;2:107-111.
5. Suzuki T, Hayakawa K, Ainai A, et al. Effectiveness of personal protective equipment in preventing severe acute respiratory syndrome coronavirus 2 infection among healthcare workers. *J Infect Chemother*. in press.
6. National Institute of Infectious Diseases. *Infect Agents Surveillance Rep*. 2020; 41:76-77. Available at

- 138 <<https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov/2488-idsc/iasr-news/9525-483p0>
139 1.html> Accessed August 15, 2020. Japanese.
- 140 7. National Institute of Infectious Diseases. Infect Agents Surveillance Rep. 2020; 41:78-79.
141 Available at
142 <<https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov/2488-idsc/iasr-news/9527-483p0>
143 2.html> Accessed August 15, 2020. Japanese.
- 144 8. National Institute of Infectious Diseases. Infect Agents Surveillance Rep. 2020; 41:79-80.
145 Available at
146 <<https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov/2488-idsc/iasr-news/9528-483p0>
147 3.html> Accessed August 15, 2020. Japanese.
- 148 9. National Institute of Infectious Diseases. Infect Agents Surveillance Rep. 2020; 41:80-82.
149 Available at
150 <<https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov/2488-idsc/iasr-news/9557-483p0>
151 4.html> Accessed August 15, 2020. Japanese.
- 152 10. Wang W, Min Y, Yang C, et al. Association of Personal Protective Equipment Use with
153 Successful Protection against COVID-19 Infection among Health Care Workers. medRxiv
154 2020.04.24.20070169.
- 155 11. Liu M, Cheng SZ, Xu KW, et al. Use of personal protective equipment against coronavirus
156 disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. BMJ.
157 2020;369:m2195.
- 158 12. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel

159 coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344.

160

161

Table 1. Characteristics of participants and timing of blood sampling

Characteristics of participants					
No.	Number of participated Operation	Content of operation	PPE compliance	Any symptom after operation	Other potential exposure to COVID-19 case
1	4	Lead patients, triage	80	No	No
2	N/A	N/A	N/A	N/A	N/A
3	2	Interview, collect specimen, lead patients	90	No	No
4	5	Interview	90	Yes	Yes
5	1	Interview, collect specimen	80	Yes	No
6	4	Interview, lead patients	100	No	Yes

7	N/A	N/A	N/A	N/A	N/A
8	2	Reception, lead patients	70	No	No
9	2	Reception, lead patients	90	No	No
10	1	Lead patients	90	No	No

N/A: not applicable (no response to questionnaire). PPE compliance was self-reported.